Literature DB >> 27501368

Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.

M V Ragni1,2, M Alabek3, L M Malec3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27501368     DOI： 10.1111/hae.13032

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  4 in total

1.  The design of a Bayesian platform trial to prevent and eradicate inhibitors in patients with hemophilia.

Authors:  Marnie Bertolet; Maria M Brooks; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-11-10

Review 2.  Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia

Authors:  Richard S Blumberg; David Lillicrap
Journal:  Blood       Date:  2018-03-27       Impact factor: 22.113

Review 3.  From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.

Authors:  David W Scott
Journal:  Front Immunol       Date:  2017-11-13       Impact factor: 7.561

Review 4.  The Neonatal Fc Receptor (FcRn): A Misnomer?

Authors:  Michal Pyzik; Kine M K Sand; Jonathan J Hubbard; Jan Terje Andersen; Inger Sandlie; Richard S Blumberg
Journal:  Front Immunol       Date:  2019-07-10       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.